LINAGLIPTIN 5mg. IP + DAPAGLIFLOZIN 10mg. IP

Belongs to the group of anti-diabetic medicines used to treat type 2 diabetes mellitus. Effectively lowers glucose levels and maintains good tolerability in patients with type 2 diabetes who were inadequately controlled with metformin and linagliptin. (Jun Hwa Hon, 2024) A superior choice for managing uncontrolled hyperglycaemia in T2D patients when compared to sulfonylureas or insulin therapy. (Jun Hwa Hon, 2024) A promising therapeutic option over linagliptin for patients with T2DM on metformin monotherapy. (Aditi Jain, 2023) Shows significant efficacy in lowering HbA1c, FPG, PPG, and body weight in patients with T2DM. (Aditi Jain, 2023) A valuable new treatment option for T2DM patients, particularly in India, where metformin is often the first choice of therapy. (Aditi Jain, 2023) Offers clinically significant improvements in glycemic control over the dapagliflozin and vildagliptin combination. (Mala Dharmalingam, 2024) A better alternative for T2DM patients inadequately controlled on metformin monotherapy. (Mala Dharmalingam, 2024)